ASP 0113

Drug Profile

ASP 0113

Alternative Names: ASP-0113; ASP0113 CMV Therapeutic Vaccine; Cytomegalovirus DNA vaccine bivalent - Vical; TransVax; VCL-CB01

Latest Information Update: 03 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vical
  • Developer Astellas Pharma
  • Class Cytomegalovirus vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 30 Apr 2018 Discontinued - Phase-III for Cytomegalovirus infections (Prevention) in USA, Japan, Australia, Canada, Belgium, Germany, Spain, South Korea, Sweden, Taiwan, France (IM) (Astellas Pharma pipeline, May 2018)
  • 22 Jan 2018 Efficacy and adverse events data from the phase III HELIOS trial in Cytomegalovirus infections released by Astellas Pharma
  • 12 Oct 2017 Vical completes a phase III trial in Cytomegalovirus infections (Prevention) in USA, Australia, Canada, Germany, Japan, South Korea, Belgium, France, Germany, Spain, Sweden and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top